Evidence map›Paper›PMID 17457158›Full record

Trial reportAnnals of surgery2007

Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study.

E Patchen Dellinger, Jose M Tellado, Norberto E Soto, Stanley W Ashley, Philip S Barie, Thierry Dugernier, Clement W Imrie, Colin D Johnson, Hanns-Peter Knaebel, Pierre-Francois Laterre and 4 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of surgery, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 12 pooled it
35.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 12 syntheses or guidelines pooled it, 362 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pharmacological interventions for acute pancreatitis.The Cochrane database of systematic reviews · 2017
    Pooled it
  8. Role of antibiotic prophylaxis in necrotizing pancreatitis: a meta-analysis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2015
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. A double-blind, placebo-controlled trial of ciprofloxacin prophylaxis in patients with acute necrotizing pancreatitis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2009
    Trial
  14. Observational
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 5 countries.

E Patchen DellingerDivision of General Surgery, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA. patch@u.washington.edu
Jose M Tellado
Norberto E Soto
Stanley W Ashley
Philip S Barie
Thierry Dugernier
Clement W Imrie
Colin D Johnson
Hanns-Peter Knaebel
Pierre-Francois Laterre
Enrique Maravi-Poma
Jorge J Olsina Kissler
Miguel Sanchez-Garcia
Stefan Utzolino
AstraZeneca (United States) · USClinique Saint Pierre · BECornell University · USHeidelberg University · DEUniversity of Freiburg · DEUniversity of Washington · USBrigham and Women's Hospital · USHospital Virgen del Camino · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsIn patients with severe, necrotizing pancreatitis, it is common to administer early, broad-spectrum antibiotics, often a carbapenem, in the hope of reducing the incidence of pancreatic and peripancreatic infections, although the benefits of doing so have not been proved.

methodsA multicenter, prospective, double-blind, placebo-controlled randomized study set in 32 centers within North America and Europe.

participantsOne hundred patients with clinically severe, confirmed necrotizing pancreatitis: 50 received meropenem and 50 received placebo.

interventionsMeropenem (1 g intravenously every 8 hours) or placebo within 5 days of the onset of symptoms for 7 to 21 days.

main outcome measuresPrimary endpoint: development of pancreatic or peripancreatic infection within 42 days following randomization. Other endpoints: time between onset of pancreatitis and the development of pancreatic or peripancreatic infection; all-cause mortality; requirement for surgical intervention; development of nonpancreatic infections within 42 days following randomization.

resultsPancreatic or peripancreatic infections developed in 18% (9 of 50) of patients in the meropenem group compared with 12% (6 of 50) in the placebo group (P = 0.401). Overall mortality rate was 20% (10 of 50) in the meropenem group and 18% (9 of 50) in the placebo group (P = 0.799). Surgical intervention was required in 26% (13 of 50) and 20% (10 of 50) of the meropenem and placebo groups, respectively (P = 0.476).

conclusionsThis study demonstrated no statistically significant difference between the treatment groups for pancreatic or peripancreatic infection, mortality, or requirement for surgical intervention, and did not support early prophylactic antimicrobial use in patients with severe acute necrotizing pancreatitis.

Indexed as

AdolescentAdultAgedAged, 80 and overAnti-Bacterial AgentsBacterial InfectionsCohort StudiesDouble-Blind MethodDrug Administration ScheduleFemaleHumansInfusions, IntravenousMaleMeropenemMiddle AgedPancreatitis, Acute NecrotizingAnti-Bacterial AgentsMeropenemThienamycins

Identifiers

PMID17457158
PMCPMC1877078
OpenAlexW1986583614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.